Shannon Westin, MD, MPH
The University of Texas
MD Anderson Cancer Center
Dr. Westin received her doctorate of Medicine from the University of Florida College of Medicine. She completed Obstetrics and Gynecology residency at the University of North Carolina – Chapel Hill and fellowship in Gynecologic Oncology at the University of Texas MD Anderson Cancer Center. During fellowship, she received an MPH with a concentration in epidemiology from the University of Texas, School of Public Health. In addition to her training in Gynecologic Oncology, she also completed a short fellowship in Investigational Cancer Therapeutics. She joined the faculty at The University of Texas MD Anderson Cancer Center in 2010. She has been honored as a K12 scholar, Andrew Sabin Family Fellow, and a Gynecologic Oncology Group Foundation Scholar Investigator.
Dr. Westin focuses on developmental therapeutics and the use of biomarkers to predict response and recurrence in gynecologic malignancies. She currently serves as the Director of Early Drug Development and Phase I trials in her department and is a Co-Director of the Ovarian Cancer Moonshot. Dr. Westin is a member of the NRG Oncology – GOG Developmental Therapeutics, Phase I, and Early Phase Protocol Oversight committees. She is the co-PI for major projects in her institution’s SPORE in Uterine Cancer and SPORE in Ovarian Cancer. In addition, she is currently the PI or co-PI for greater than 20 novel treatment trials in gynecologic malignancies.
Dr. Westin has authored or co-authored greater than 100 scientific publications, book chapters and invited articles. She has been invited to lecture as an expert on clinical trials, genomic testing and targeted therapy in gynecologic malignancies in national and international venues. She was selected for the competitive American Society of Clinical Oncology (ASCO) Leadership Development program and serves on five ASCO committees including the Communications Committee and Gynecologic Cancer Guidelines Group. She is an active member of the International Gynecologic Cancer Society and the Society of Gynecologic Oncology (SGO) and served on the Program Committee for the 2020 SGO Annual Meeting. In addition to serving on the National Cancer Institute (NCI) Uterine Task Force and Gynecologic Cancer Steering Committee (GCSC), she serves as a co-chair of the GCSC Ovarian Cancer Task Force and the NCI Ovarian Cancer Clinical Trials Planning Meeting. As such, she is guiding development of future NCI trials designed to push the field forward and expand the role of precision medicine in ovarian cancer.
- On-Demand Clinical Presentation: Managing Drug Class Toxicities – PARP Inhibitors in Gynecologic Cancers
- Panelist: Solid Tumor Clinical Panel Discussions